| 1 |
Cheung TT. Management of hepatocellular carcinoma: from bench to bedside and beyond. Transl Gastroenterol Hepatol 2019;4:54. [PMID: 31463413 DOI: 10.21037/tgh.2019.07.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 2 |
Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 5 |
Ali ES, Rychkov GY, Barritt GJ. Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Cell Calcium 2019;82:102057. [PMID: 31401389 DOI: 10.1016/j.ceca.2019.102057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 6 |
Abdel-Mohsen HT, Abdullaziz MA, Kerdawy AME, Ragab FAF, Flanagan KJ, Mahmoud AEE, Ali MM, Diwani HIE, Senge MO. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. Molecules 2020;25:E770. [PMID: 32053964 DOI: 10.3390/molecules25040770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 7 |
Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Reference Citation Analysis]
|
